I'm LongbridgeAI. Here is the key information I extracted- The broker raised Pfizer, Inc.’s target price from USD 27 to USD 30 while maintaining a Neutral rating, citing improved core business stability despite upcoming patent expiry pressures.…
UBS published a research report stating that Pfizer, Inc. (PFE.US) 's third-quarter results beat expectations, with quarterly revenue of USD16.58 billion, above market expectations of USD15.85 billion. EPS was USD0.87, higher than market expectations of USD0.73. Management raised full-year revenue guidance to between USD62 billion and USD64 billion, with the midpoint of guidance increased by USD1.5 billion from USD61.5 billion to USD63 billion. Multiple projects in the product pipeline continued to advance.
The broker believes the improved results will help stabilize the core business. However, the company still faces patent expiry pressure of about USD15 billion to USD20 billion over the next few years, and whether it can fill the patent gap through 2030 remains to be seen. It expects a key near-term catalyst to be the Phase III data for MEVPRO-1 in second-line metastatic castration-resistant prostate cancer in 1Q27.
The broker raised its TP on Pfizer, Inc. (PFE.US) from USD27 to USD30, corresponding to about 10x to 11x its 2027 EPS forecast, while maintaining a Neutral rating.(gc/da)(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
